Health
FDA grants rare disease designations to investigational brain tumor drug – News-Medical.Net
The U.S. Food and Drug Administration has awarded Rare Pediatric Disease Designation (RPDD) for diffuse intrinsic pontine glioma (DIPG) and Orphan Drug Designation for treatment of malignant glioma to OKN-007, an investigational drug discovered at the Oklahom…
Reviewed by Emily Henderson, B.Sc.Sep 2 2020
The U.S. Food and Drug Administration has awarded Rare Pediatric Disease Designation (RPDD) for diffuse intrinsic pontine glioma (DIPG) and Orphan Drug Designation for treatment of malignant glioma to OKN-007, an investigational drug discovered at the Oklahoma Medical Research Foundation and being developed by Oblato, Inc.
DIPG is a fast-growing pediatric cancer that starts in the brain stem. It is one of several sub-categories of malignant gliomas,…
-
General18 hours agoRSL NSW president Mick Bainbridge and three board members resign in wake of 7.30 investigation into conflicts of interest
-
General21 hours agoSelf-taught child drummer makes rock band debut with The Living End
-
Noosa News17 hours agoNorman Dean Lake refused bail for allegedly threatening to kill Prime Minister Anthony Albanese
-
General24 hours agoFirst Nations children’s commissioner must have power to make change: advocates